Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure

BLOOD ADVANCES

AMER SOC HEMATOLOGY

1. NCATS NIH HHS [UL1 TR001863] Funding Source: Medline
2. NCI NIH HHS [P30 CA008748, P01 CA214278] Funding Source: Medline